Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

• Autori principali: Xiang Zhang (Autore), Jiejing Qian (Autore), Huafeng Wang (Autore), Yungui Wang (Autore), Yi Zhang (Autore), Pengxu Qian (Autore), Yinjun Lou (Autore), Jie Jin (Autore), Honghu Zhu (Autore)
• Natura: Libro
• Pubblicazione: BMC, 2021-05-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Venetoclax (VEN) plus azacitidine has become the first-line therapy for elderly patients with acute myeloid leukemia (AML), and has a complete remission (CR) plus CR with incomplete recovery of hemogram rate of ≥70%. However, the 3-year survival rate of these patients is < 40% due to rel...